NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced that Julian S. Gangolli, President, North
America, of GW Pharmaceuticals plc, has been elected to Revance's Board
of Directors and will serve as a member of the Audit Committee,
effective July 1, 2016.
Mr. Gangolli brings over two decades of senior management experience
building and running operations and product commercialization for
leading biopharma firms. He was a member of the executive management
team that transformed Allergan into one of the leading global specialty
pharmaceutical companies.
"We are thrilled to add Julian Gangolli to our Board of Directors.
Julian has a distinguished track record successfully overseeing product
and brand strategy, commercialization campaigns and business development
activities in specialties such as dermatology, neurology, and
ophthalmology," said Dan Browne, President and Chief Executive Officer
at Revance. "Julian had direct involvement in the extraordinary growth
of the botulinum toxin market. He will be invaluable as we continue to
progress toward regulatory approval and commercialization of RT002
injectable, our novel neurotoxin product candidate, and further expand
our pipeline into a variety of therapeutic areas."
"I am delighted to work with the Board and Revance's executive team to
develop and commercialize the first truly novel botulinum toxin platform
in nearly three decades," said Mr. Gangolli. "I believe the company's
focus on new botulinum toxin formulations, with truly differentiated
properties to treat existing and new indications, has the potential to
position Revance to become a market leader in neuromodulation. I look
forward to being part of the company's success."
Mr. Gangolli is President, North America of GW Pharmaceuticals,
spearheading the buildout of the company's U.S. commercial
infrastructure in advance of the potential launch of its lead
therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in
late-stage development for diverse indications. Prior to joining GW
Pharma, Mr. Gangolli served as President of the North American
Pharmaceutical division of Allergan Inc. for 11 years, where he was
responsible for a 1,400 person integrated commercial operation with
sales exceeding $3.8 billion in 2014. Previously, he served as Senior
Vice President, U.S. Eye Care at Allergan, during which time this
division launched eight new products, helping to propel growth at more
than 20% a year over a 5‐year period. Prior to Allergan, Mr. Gangolli
served as Vice President, Sales and Marketing at VIVUS, Inc., where he
facilitated the successful transition of the company from a research and
development start-up into a niche pharmaceutical company. Before VIVUS,
Mr. Gangolli served in a number of increasingly senior marketing roles
at Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in
the UK. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry
and Business Studies from Kingston University in England.
Concurrent with Mr. Gangolli's appointment, James Glasheen, Ph.D., will
step down from the Revance Board of Directors. "Since joining our board
in 2004, Jim has been a valued advisor, seeing us from our early
development phase, through the initial public offering and now into
late-stage development of our neurotoxin," said Browne. "Through
Technology Partners, Jim was an important early investor in the company
and is now making a natural transition to other venture opportunities.
We appreciate the strategic guidance and financial acumen he brought to
our Audit Committee and boardroom and thank him for his many years of
contributions."
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology and neurology. Revance's trajectory
to commercial success begins with the company's novel and proprietary
TransMTS® carrier-peptide delivery system applied to botulinum toxin.
Revance is developing daxibotulinumtoxinA, the company's highly purified
botulinum toxin, for a broad spectrum of aesthetic and therapeutic
indications, including facial wrinkles and muscle movement disorders.
The company holds worldwide rights for all indications of
DaxibotulinumtoxinA Topical Gel (RT001), DaxibotulinumtoxinA for
Injection (RT002) and the TransMTS technology platform. Beyond botulinum
toxin, Revance believes the TransMTS technology can be applied to
transdermal, mid-dermal, or deep tissue delivery of a variety of other
macromolecules. More information on Revance can be found at www.revance.com.
"Revance Therapeutics", TransMTS®, "Remarkable Science Changes
Everything", and the Revance logo are registered trademarks of Revance
Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements, including,
but not limited to: statements about our business strategy, our
investigational drug product candidates, expected efficacy of our drug
product candidates, clinical development, timeline and other goals and
market for our anticipated products, plans and prospects and statements
about potential benefits of our drug product candidates and our
technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective design
or generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; our ability to
obtain funding for our operations; our plans to research, develop, and
commercialize our drug product candidates; our ability to achieve market
acceptance of our drug product candidates; unanticipated costs or delays
in research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the size and
growth potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates and
the timing of commercialization activities; the rate and degree of
market acceptance of our drug product candidates; our ability to develop
sales and marketing capabilities; the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for
financing; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates; and
other risks. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"SEC"), including factors described in the section entitled "Risk
Factors" of our quarterly report on Form 10-Q filed on May 10, 2016.
These forward-looking statements speak only as of the date hereof.
Revance disclaims any obligation to update these forward-looking
statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160705005230/en/
Investors:
Revance Therapeutics
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Burns
McClellan
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media
